THERAPEUTIC MONITORING OF LEVOFLOXACIN: A NEW LC-MS/MS METHOD FOR QUANTIFICATION OF LEVOFLOXACIN IN HUMAN PLASMA

被引:0
作者
Tilea, Brindusa [1 ]
Vlase, Laurian [2 ]
Popa, Daniela-Saveta [2 ]
Primejdie, Daniela [2 ]
Muntean, Daniela Lucia [3 ]
Tilea, Ioan [1 ]
机构
[1] Univ Med & Pharm Tirgu Mures, Fac Med, RO-540139 Targu Mures, Romania
[2] Univ Med & Pharm Iuliu Hatieganu, Fac Pharm, RO-400023 Cluj Napoca, Romania
[3] Univ Med & Pharm Tirgu Mures, Fac Pharm, RO-540139 Targu Mures, Romania
来源
STUDIA UNIVERSITATIS BABES-BOLYAI CHEMIA | 2013年 / 58卷 / 01期
关键词
levofloxacin; LC-MS/MS; therapeutic drug monitoring; TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; OXIDATIVE STRESS INDUCTION; SOLID-PHASE EXTRACTION; 500; MG; SINGLE; VOLUNTEERS; RIFAMPICIN; URINE; PHARMACOKINETICS;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A simple and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method for the quantification of levofloxacin in human plasma was developed and validated. The separation was performed on a Zorbax SB-C18 column under isocratic conditions using a mobile phase of 17:83 (v/v) acetonitrile and 0.1% (v/v) formic acid in water at 50 degrees C with a flow rate of 1 mL/min. The detection of levofloxacin was performed in multiple reaction monitoring (MRM) mode using an ion trap mass spectrometer with electrospray positive ionisation. The human plasma samples (0.1 mL) were deproteinised with methanol and aliquots of 1 mu L from supernatants obtained after centrifugation were directly injected into the chromatographic system. The method shows a good linearity (r(2) > 0.99), precision (CV < 11%) and accuracy (bias < 4.7%) over the range of 0.1-10.0 mu g/mL plasma. The lower limit of quantification (LLOQ) was 0.1 mu g/mL and the recovery was between 95.2-104.5%. The method is not expensive, it needs a minimum time for plasma sample preparation and has a run-time of 1.3 min for instrument analysis (retention time of levofloxacin was 0.9 min). The developed and validated method is very simple, rapid and efficient, with wide applications in clinical level monitoring, pharmacokinetics and bioequivalence studies of levofloxacin.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 34 条
[1]  
Anderson P., 2002, HDB CLIN DRUG DATA, P167
[2]  
[Anonymous], 2011, ANAL METHODS THERAPE
[3]  
[Anonymous], 2001, CPMPEWPQWP140198 EUR
[4]  
[Anonymous], 2001, FED REGISTER, P66
[5]   Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV [J].
Baietto, Lorena ;
D'Avolio, Antonio ;
De Rosa, Francesco Giuseppe ;
Garazzino, Silvia ;
Patanella, Samantha ;
Siccardi, Marco ;
Sciandra, Matiro ;
Di Perri, Giovanni .
THERAPEUTIC DRUG MONITORING, 2009, 31 (01) :104-109
[6]   Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry [J].
Bao, Donghui ;
Truong, Thanh-Thai ;
Renick, Paul J. ;
Pulse, Mark E. ;
Weiss, William J. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 46 (04) :723-727
[7]  
Das A, 2011, ARZNEIMITTELFORSCH, V61, P61, DOI 10.1055/s-0031-1296168
[8]   Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry [J].
Fang, Ping-Fei ;
Cai, Hua-Lin ;
Li, Huan-De ;
Zhu, Rong-Hua ;
Tan, Qin-You ;
Gao, Wei ;
Xu, Ping ;
Liu, Yi-Ping ;
Zhang, Wen-Yuan ;
Chen, Yong-Chang ;
Zhang, Feng .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2010, 878 (24) :2286-2291
[9]   Bioavailability of Two Oral Formulations of a Single Dose of Levofloxacin 500 mg: An Open-Label, Randomized, Two-Period Crossover Comparison in Healthy Mexican Volunteers [J].
Galan-Herrera, Juan Francisco ;
Poo, Jorge Luis ;
Rosales-Sanchez, Oscar ;
Fuentes-Fuentes, Elvira ;
Carino, Lizbeth ;
Burke-Fraga, Victoria ;
Namur, Salvador ;
Gonzalez-de la Parra, Mario .
CLINICAL THERAPEUTICS, 2009, 31 (08) :1796-1803
[10]  
Gao XX, 2007, DRUG DISCOV THER, V1, P136